As Alnylam Files to Begin Testing Cholesterol Drug in Humans, Questions Linger Over Delivery Tech

Alnylam said that the drug candidate is the first to incorporate the company's second-generation lipid nanoparticle technology. However, Alnylam is currently embroiled in a lawsuit with partner Tekmira Pharmaceuticals over ownership of that very delivery technology.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.